Small molecule inhibitors of CXCR4

Theranostics

Volumn 3, Issue 1, 2013, Pages 47-75

  Debnath, Bikash ^a   Xu, Shili ^a   Grande, Fedora ^b   Garofalo, Antonio ^b   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Antagonists; Cancer; CXCR4; HIV; Lupus; Rheumatoid arthritis; WHIM syndrome

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; BIS TETRAAZAMACROCYCLE DERIVATIVE; BUTANEDIAMINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 MONOCLONAL ANTIBODY; CTCE 9908; DACARBAZINE; DIETHYLENETRIAMINE; FC 122; FC 131; INDOLE DERIVATIVE; KRH 3955; MONOCLONAL ANTIBODY; MSX 122; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; NB 325; PLERIXAFOR; POL 6326; SMALL INTERFERING RNA; SPERMIDINE; SPERMINE; SULFONE DERIVATIVE; T 140; TETRAHYDROQUINOLINE DERIVATIVE; TG 0054; TN 14003; TRISBUTYLAMINOMELANINE; TRISHEXYLAMINOMELANINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTIVIRAL ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; DRUG ABSORPTION; DRUG APPROVAL; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; GLIOMA; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNE DEFICIENCY; LEUKEMIA; LUNG FIBROSIS; LUNG SMALL CELL CANCER; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; STEM CELL MOBILIZATION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; WARTS HYPOGAMMAGLOBULINEMIA INFECTION AND MYELOKATHEXIS SYNDROME;

ANTAGONISTS; CANCER; CXCR4; HIV; LUPUS.; RHEUMATOID ARTHRITIS; WHIM SYNDROME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE; HUMANS; RECEPTORS, CXCR4; SMALL MOLECULE LIBRARIES;

EID: 84883198880     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5376     Document Type: Review

References (129)

1. Lefrancois M, Lefebvre MR, Saint-Onge G, Boulais PE, Lamothe S, Leduc R, et al. Agonists for the Chemokine Receptor CXCR4. ACS Med Chem Lett. 2011; 2: 597-602.
2. Zhan W, Liang Z, Zhu A, Kurtkaya S, Shim H, Snyder JP, et al. Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007; 50: 5655-64.
3. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997; 94: 1925-30.
4. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996; 382: 833-5.
5. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996; 382: 829-33.
6. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007; 25: 787-820.
7. Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and disease. Exp Cell Res. 2011; 317: 575-89.
8. Balkwill FR. The chemokine system and cancer. J Pathol. 2012; 226: 148-57.
9. Fagete S, Ravn U, Gueneau F, Magistrelli G, Kosco-Vilbois MH, Fischer N. Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent. MAbs. 2009; 1: 288-96.
10. Woodard LE, Nimmagadda S. CXCR4-based imaging agents. J Nucl Med. 2011; 52: 1665-9.
11. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010; 330: 1066-71.
12. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. Embo J. 1997; 16: 6996-7007.
13. Didigu CA, Doms RW. Novel Approaches to Inhibit HIV Entry. Viruses. 2012; 4: 309-24.
14. Azevedo-Pereira JM, Santos-Costa Q. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications]. Acta Med Port. 2008; 21: 497-504.
15. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr Pharm Des. 2004; 10: 2041-62.
16. Cervia JS, Smith MA. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis. 2003; 37: 1102-6.
17. Grande F, Garofalo A, Neamati N. Small molecules anti-HIV therapeutics targeting CXCR4. Curr Pharm Des. 2008; 14: 385-404.
18. Wilen CB, Tilton JC, Doms RW. Molecular mechanisms of HIV entry. Adv Exp Med Biol. 2012; 726: 223-42.
19. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med. 1997; 185: 621-8.
20. Sucupira MC, Sanabani S, Cortes RM, Giret MT, Tomiyama H, Sauer MM, et al. Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains. PLoS One. 2012; 7: e30292.
21. Raymond S, Delobel P, Mavigner M, Cazabat M, Encinas S, Souyris C, et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. Aids. 2010; 24: 2305-12.
22. Furusato B, Mohamed A, Uhlen M, Rhim JS. CXCR4 and cancer. Pathol Int. 2010; 60: 497-505.
23. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999; 94: 3658-67.
24. Mohle R, Failenschmid C, Bautz F, Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia. 1999; 13: 1954-9.
25. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005; 106: 1824-30.
26. Bradstock KF, Makrynikola V, Bianchi A, Shen W, Hewson J, Gottlieb DJ. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia. 2000; 14: 882-8.
27. Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998; 91: 4523-30.
28. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410: 50-6.
29. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004; 6: 459-69.
30. Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene. 2003; 22: 8093-101.
31. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002; 62: 6304-11.
32. Wang J, Sun Y, Song W, Nor JE, Wang CY, Taichman RS. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal. 2005; 17: 1578-92.
33. Barbolina MV, Kim M, Liu Y, Shepard J, Belmadani A, Miller RJ, et al. Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res. 2010; 8: 653-64.
34. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003; 63: 3833-9.
35. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol. 2010; 20: 424-30.
36. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005; 65: 967-71.
37. Li RJ, Zhao LJ, Zhan ZL, Lu X, Gong LL, Wang P. [Significance of expression of chemokine receptor and matrix metalloproteinase in small cell lung cancer]. Zhonghua Yi Xue Za Zhi. 2012; 92: 532-5.
38. Gladson CL, Welch DR. New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biol Ther. 2008; 7: 1849-51.
39. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci. 2008; 99: 539-42.
40. Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K, et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 2010; 70: 10411-21.
41. Franco R, Botti G, Mascolo M, Loquercio G, Liguori G, Ilardi G, et al. "CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression". Front Biosci (Elite Ed). 2010; 2: 13-21.
42. Chung SH, Seki K, Choi BI, Kimura KB, Ito A, Fujikado N, et al. CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis. Arthritis Res Ther. 2010; 12: R188.
43. De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, Vermeire K, et al. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther. 2005; 7: R1208-20.
44. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol. 2000; 165: 3423-9.
45. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003; 34: 70-4.
46. Bachelerie F. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome. Dis Markers. 2010; 29: 189-98.
47. Wen J, Zhang JQ, Huang W, Wang Y. SDF-1alpha and CXCR4 as therapeutic targets in cardiovascular disease. Am J Cardiovasc Dis. 2012; 2: 20-8.
48. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10: 858-64.
49. Misao Y, Takemura G, Arai M, Ohno T, Onogi H, Takahashi T, et al. Importance of recruitment of bone marrow-derived CXCR4+ cells in post-infarct cardiac repair mediated by G-CSF. Cardiovasc Res. 2006; 71: 455-65.
50. Song JS, Kang CM, Kang HH, Yoon HK, Kim YK, Kim KH, et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med. 2010; 42: 465-72.
51. Wang A, Guilpain P, Chong BF, Chouzenoux S, Guillevin L, Du Y, et al. Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis Rheum. 2010; 62: 3436-46.
52. Chong BF, Mohan C. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2009; 13: 1147-53.
53. Wang A, Fairhurst AM, Tus K, Subramanian S, Liu Y, Lin F, et al. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J Immunol. 2009; 182: 4448-58.
54. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs. 2009; 18: 481-90.
55. Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S. Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res. 2007; 13: 1562-70.
56. Wilson LJ, Liotta DC. Emergence of small-molecule CXCR4 antagonists as novel immune and hematopoietic system regulatory agents. Drug Development Research. 2011; 72: 598-602.
57. Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med. 2007; 58: 445-59.
58. Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets. 2005; 9: 1267-82.
59. Fujii N, Nakashima H, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs. 2003; 12: 185-95.
60. Zhou N, Luo Z, Luo J, Fan X, Cayabyab M, Hiraoka M, et al. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J Biol Chem. 2002; 277: 17476-85.
61. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996; 381: 667-73.
62. Tanaka T, Nomura W, Narumi T, Esaka A, Oishi S, Ohashi N, et al. Structure-activity relationship study on artificial CXCR4 ligands possessing the cyclic pentapeptide scaffold: the exploration of amino acid residues of pentapeptides by substitutions of several aromatic amino acids. Org Biomol Chem. 2009; 7: 3805-9.
63. Tanaka T, Tsutsumi H, Nomura W, Tanabe Y, Ohashi N, Esaka A, et al. Structure-activity relationship study of CXCR4 antagonists bearing the cyclic pentapeptide scaffold: identification of the new pharmacophore. Org Biomol Chem. 2008; 6: 4374-7.
64. Tamamura H, Esaka A, Ogawa T, Araki T, Ueda S, Wang Z, et al. Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Org Biomol Chem. 2005; 3: 4392-4.
65. Fujii N, Oishi S, Hiramatsu K, Araki T, Ueda S, Tamamura H, et al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew Chem Int Ed Engl. 2003; 42: 3251-3.
66. Ueda S, Oishi S, Wang ZX, Araki T, Tamamura H, Cluzeau J, et al. Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J Med Chem. 2007; 50: 192-8.
67. Tamamura H, Araki T, Ueda S, Wang Z, Oishi S, Esaka A, et al. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem. 2005; 48: 3280-9.
68. Tamamura H, Hiramatsu K, Ueda S, Wang Z, Kusano S, Terakubo S, et al. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J Med Chem. 2005; 48: 380-91.
69. Narumi T, Hayashi R, Tomita K, Kobayashi K, Tanahara N, Ohno H, et al. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. Org Biomol Chem. 2010; 8: 616-21.
70. Inokuchi E, Oishi S, Kubo T, Ohno H, Shimura K, Matsuoka M, et al. Potent CXCR4 antagonists containing amidine type peptide bond isosteres. ACS Med Chem Lett. 2011; 2: 477-80.
71. Oishi S, Kamitani H, Kodera Y, Watanabe K, Kobayashi K, Narumi T, et al. Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres: synthesis and bioevaluation of alpha-helical anti-HIV peptide analogues. Org Biomol Chem. 2009; 7: 2872-7.
72. Kobayashi K, Narumi T, Oishi S, Ohno H, Fujii N. Amino acid-based synthesis of trifluoromethylalkene dipeptide isosteres by alcohol-assisted nucleophilic trifluoromethylation and organozinc-copper-mediated S(N)2' alkylation. J Org Chem. 2009; 74: 4626-9.
73. Yamaki Y, Shigenaga A, Li J, Shimohigashi Y, Otaka A. Synthesis of amide-type fluoroalkene dipeptide isosteres by an intramolecular redox reaction. J Org Chem. 2009; 74: 3278-85.
74. Dai N, Wang XJ, Etzkorn FA. The effect of a trans-locked Gly-Pro alkene isostere on collagen triple helix stability. J Am Chem Soc. 2008; 130: 5396-7.
75. Wiktelius D, Luthman K. Taking control of P1, P1' and double bond stereochemistry in the synthesis of Phe-Phe (E)-alkene amide isostere dipeptidomimetics. Org Biomol Chem. 2007; 5: 603-5.
76. Bandur NG, Harms K, Koert U. First stereoselective snthesis of a Tyr-Tyr E-alkene isostere. Synlett. 2007;: 99-102.
77. Jones RCF, Ward GJ. Amide bond isosteres: imidazolines in pseudopeptide chemistry. Tetrahedron Lett. 1988; 29: 3853-6.
78. Kiessling LL, Gestwicki JE, Strong LE. Synthetic multivalent ligands as probes of signal transduction. Angew Chem Int Ed Engl. 2006; 45: 2348-68.
79. Kiessling LL, Gestwicki JE, Strong LE. Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol. 2000; 4: 696-703.
80. Li ZB, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging. 2008; 35: 1100-8.
81. Demmer O, Dijkgraaf I, Schumacher U, Marinelli L, Cosconati S, Gourni E, et al. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J Med Chem. 2011; 54: 7648-62.
82. Tanaka T, Nomura W, Narumi T, Masuda A, Tamamura H. Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells. J Am Chem Soc. 2010; 132: 15899-901.
83. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem. 2011; 6: 1789-91.
84. Ueda S, Kato M, Inuki S, Ohno H, Evans B, Wang ZX, et al. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett. 2008; 18: 4124-9.
85. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000; 44: 1667-73.
86. Moyle G, DeJesus E, Boffito M, Wong RS, Gibney C, Badel K, et al. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis. 2009; 48: 798-805.
87. Skerlj R, Bridger G, McEachern E, Harwig C, Smith C, Kaller A, et al. Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. Bioorg Med Chem Lett. 2011; 21: 1414-8.
88. Skerlj R, Bridger G, McEachern E, Harwig C, Smith C, Wilson T, et al. Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication. Bioorg Med Chem Lett. 2011; 21: 262-6.
89. Miller JF, Gudmundsson KS, D'Aurora Richardson L, Jenkinson S, Spaltenstein A, Thomson M, et al. Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity. Bioorg Med Chem Lett. 2010; 20: 3026-30.
90. Miller JF, Turner EM, Gudmundsson KS, Jenkinson S, Spaltenstein A, Thomson M, et al. Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents. Bioorg Med Chem Lett. 2010; 20: 2125-8.
91. Catalano JG, Gudmundsson KS, Svolto A, Boggs SD, Miller JF, Spaltenstein A, et al. Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett. 2010; 20: 2186-90.
92. Gudmundsson KS, Boggs SD, Catalano JG, Svolto A, Spaltenstein A, Thomson M, et al. Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1. Bioorg Med Chem Lett. 2009; 19: 6399-403.
93. Gudmundsson KS, Sebahar PR, Richardson LD, Miller JF, Turner EM, Catalano JG, et al. Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett. 2009; 19: 5048-52.
94. Bridger GJ, Skerlj RT, Hernandez-Abad PE, Bogucki DE, Wang Z, Zhou Y, et al. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. J Med Chem. 2010; 53: 1250-60.
95. Bodart V, Anastassov V, Darkes MC, Idzan SR, Labrecque J, Lau G, et al. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol. 2009; 78: 993-1000.
96. Zhu A, Zhan W, Liang Z, Yoon Y, Yang H, Grossniklaus HE, et al. Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem. 2010; 53: 8556-68.
97. Fujii N, Tamamura H. Peptide-lead CXCR4 antagonists with high anti-HIV activity. Curr Opin Investig Drugs. 2001; 2: 1198-202.
98. Wong D, Korz W. Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clin Cancer Res. 2008; 14: 7975-80.
99. Yu L, Cecil J, Peng SB, Schrementi J, Kovacevic S, Paul D, et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene. 2006; 374: 174-9.
100. Wilkinson RA, Pincus SH, Shepard JB, Walton SK, Bergin EP, Labib M, et al. Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4. Antimicrob Agents Chemother. 2011; 55: 255-63.
101. Thakkar N, Pirrone V, Passic S, Zhu W, Kholodovych V, Welsh W, et al. Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother. 2009; 53: 631-8.
102. Krebs FC, Miller SR, Ferguson ML, Labib M, Rando RF, Wigdahl B. Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed Pharmacother. 2005; 59: 438-45.
103. Kim J, Yip ML, Shen X, Li H, Hsin LY, Labarge S, et al. Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. PLoS One. 2012; 7: e31004.
104. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012; 42: 145-53.
105. Hempelmann E. Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitol Res. 2007; 100: 671-6.
106. Warhurst DC, Steele JC, Adagu IS, Craig JC, Cullander C. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother. 2003; 52: 188-93.
107. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 2010; 10: 370.
108. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep. 2010; 23: 1183-92.
109. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6.
110. Yen CF, Hu CK, Chou MC, Tseng CT, Wu CH, Huang YH, Chen SJ, King CHR. Pyrimidine compounds. US 2009/0143302 (A1). 2009.
111. Yoshida K, Ochiai H, Tani K, Shibayama S, Kasano M. Compound having spiro-bonded cyclic group and use thereof. WO 2010/147094 (A1). 2010.
112. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther. 2010; 128: 509-18.
113. Murakami T, Kumakura S, Yamazaki T, Tanaka R, Hamatake M, Okuma K, et al. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother. 2009; 53: 2940-8.
114. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A. 2003; 100: 4185-90.
115. Patel K, Dixit VD, Lee JH, Kim JW, Schaffer EM, Nguyen D, et al. Identification of ghrelin receptor blocker, D-[Lys3] GHRP-6 as a CXCR4 receptor antagonist. Int J Biol Sci. 2012; 8: 108-17.
116. Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005; 26: 346-60.
117. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005; 85: 495-522.
118. Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011; 129: 225-32.
119. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009; 155: 231-6.
120. Robinson JA, Demarco S, Gombert F, Moehle K, Obrecht D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today. 2008; 13: 944-51.
121. [Internet] NCT01339039. Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma. http://clinicaltrialsgov.
122. [Internet] NCT01141543. Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection. http://clinicaltrialsgov.
123. [Internet] NCT01373229. Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL). http://clinicaltrialsgov.
124. [Internet] NCT01058993. AMD 3100 for Treatment of Myelokathexis. http://clinicaltrialsgov.
125. [Internet] NCT01018979. Safety, Pharmacokinetics and Stem Cell Mobilization of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients. http://clinicaltrialsgov.
126. [Internet] NCT00089466. Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients. http://clinicaltrialsgov.
127. [Internet] NCT00591682. MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. http://clinicaltrialsgov.
128. [Internet] NCT01413568. Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies. http://clinicaltrialsgov.
129. Tanguy Le Carrour SA, Sylvie Tondeur, Ludovic Lhermitte, Ned Lamb, Thierry Reme, Veronique Pantesco, Samir Hamamah, Bernard Klein and John De Vos. Amazonia!: an online resource to google and visualize public human whole genome expression data. The open bioinformatics journal. 2010; 4: 5-10